Immunic, Inc.
- Last sale
- Nov 12, 2026 · -4.18%
- Market cap
- $123.87M
- 15.88M shares
- Filings
- 837
Q1 2014
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−56.6% FY25 yoy
- $123.87M
- —
- —
- 1.2×
- -69.40%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
No annual history for this metric yet.
| Period | Ended | Value | Kind | Source trail |
|---|
Pharmaceutical preparations
Immunic, Inc. is the 275th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
MENSJyong Biotech Ltd.———$130.0MNGENNervgen Pharma Corp.———$129.0MORGOOrganogenesis Holdings Inc.$564.2M17.0%6.6%$125.3M
IMUXImmunic, Inc. (this company)———$123.9M
SPRBSpruce Biosciences, Inc.$0.0100.0%—$123.8MFHTXFoghorn Therapeutics Inc.$30.9M36.8%240.3%$123.5MDERMJourney Medical Corp$61.9M10.2%18.5%$123.4MOKUROnKure Therapeutics, Inc.———$121.7MNERVMinerva Neurosciences, Inc.———$119.1MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Immunic, Inc. · CIK 1280776 · Engraved from SEC EDGAR